(Q44016352)

29 November 2017

title

Effects of gemfibrozil on insulin resistance to fat metabolism in subjects with type 2 diabetes and hypertriglyceridaemia (English)

1 reference

29 November 2017

0 references

1 reference

1 reference

Whitelaw DC

1

1 reference

29 November 2017

Smith JM

series ordinal

2

1 reference

29 November 2017

Nattrass M

series ordinal

3

1 reference

29 November 2017

publication date

1 May 2002

1 reference

Diabetes, Obesity and Metabolism

29 November 2017

published in

1 reference

29 November 2017

volume

4

1 reference

29 November 2017

issue

3

1 reference

29 November 2017

page(s)

187-194

1 reference

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00199.X

Banting lecture 1988. Role of insulin resistance in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00199.X

The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00199.X

Use of combined oral contraceptive preparations alters the insulin sensitivity of fatty acid and ketone metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00199.X

Effects of morbid obesity on insulin clearance and insulin sensitivity in several aspects of metabolism as assessed by low-dose insulin infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00199.X

Impaired glucose tolerance is characterized by multiple abnormalities in the regulation of intermediary metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00199.X

Following weight loss in massively obese patients correction of the insulin resistance of fat metabolism is delayed relative to the improvement in carbohydrate metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00199.X

Optimized methods to measure acetoacetate, 3-hydroxybutyrate, glycerol, alanine, pyruvate, lactate and glucose in human blood using a centrifugal analyser with a fluorimetric attachment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00199.X

Reappraisal of the role of insulin in hypertriglyceridemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00199.X

Hepatic insulin responsiveness in patients with endogenous hypertriglyceridaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00199.X

Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00199.X

Acyl-CoA synthetase mRNA expression is controlled by fibric-acid derivatives, feeding and liver proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00199.X

Localization and regulation of the human very low density lipoprotein/apolipoprotein-E receptor: trophoblast expression predicts a role for the receptor in placental lipid transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00199.X

Effect of gemfibrozil treatment in sulfonylurea-treated patients with noninsulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00199.X

Effects of gemfibrozil on triglyceride levels in patients with NIDDM. Hyperlipidemia in Diabetes Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00199.X

Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00199.X

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00199.X

Effect of gemfibrozil on composition of lipoproteins and distribution of LDL subspecies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00199.X

Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00199.X

Effects of bezafibrate on insulin sensitivity and glucose tolerance in subjects with combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00199.X

Lowering of triglycerides by gemfibrozil affects neither the glucoregulatory nor antilipolytic effect of insulin in type 2 (non-insulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00199.X

Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00199.X

Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00199.X

10.1046/J.1463-1326.2002.00199.X

21 January 2018

Identifiers

DOI

1 reference

29 November 2017

1 reference